This is a broad portfolio that includes all aspects of life sciences. Some of the representative areas are bioengineering (brain computer interface, chips to grow and monitor cellular activities, and bioprinting), vaccines and therapeutics (nanolipoprotein particles for the delivery of vaccines and drugs, carbon nanotubes for drug delivery, KRAS inhibitors, and anti-bacterial minerals), medical diagnostics (molecular diagnostics, point-of-care testing, imaging, and forensic), life science instrumentation (PCR instruments, rapid PCR, fluid partitioning, microfluidics, and biosensors), and methods for the extraction and purification of rare earth elements using lanmodulin and other natural/synthetic bacterial proteins.
Portfolio News and Multimedia
A Lawrence Livermore National Laboratory (LLNL) researcher and a colleague who helped him and his team commercialize their biomedical technology have garnered a national technology transfer award.
The award, from the Federal Laboratory Consortium (FLC), represents the 42nd technology transfer award that LLNL has won from the FLC since 1985.
Lawrence Livermore National Laboratory (LLNL) has joined forces with Precision Neuroscience Corporation (Precision) to advance the technology of neural implants for patients suffering from a variety of neurological disorders, including stroke, spinal cord injury and neurodegenerative diseases such as Lou Gehrig's disease.
Under the three-year collaboration, outlined in a Cooperative Research and Development Agreement (CRADA), LLNL scientists and engineers will work with Precision to develop future versions of the company’s neural implant – a thin-film microelectrode array called the Layer 7 Cortical Interface – with enhanced longevity.
The development of new antibiotics has stalled — new strategies are needed as the world enters the age of antibiotic resistance. To combat this challenge, Lawrence Livermore National Laboratory (LLNL) scientists have found that synthetic antibacterial minerals exhibit potent antibacterial activity against topical MRSA infections and increase the rate of wound closure.
A patent has been filed on this technology and Morrison’s research team is looking for industry partners to help commercialize this novel antimicrobial approach; click here for more information regarding partnership and licensing opportunities.
To replicate the physiology and functionality of tissues and organs, LLNL has developed an in vitro device that contains 3D MEAs made from flexible polymeric probes with multiple electrodes along the body of each probe. At the end of each probe body is a specially designed hinge that allows the probe to transition from lying flat to a more upright position when actuated and then…